Abstract: Age-related macular degeneration(AMD) is a major cause of blindness in elderly populations. Wet AMD, which is characterized by choroidal neovascularization (CNV), is the leading cause of vision loss. AntiVEGF therapy is the current firstline treatment for wet AMD. Aflibercept (Eylea) is the latest member in the antiVEGF drugs for ophthalmic application. The dose interval of Aflibercept can be extended but yield stable therapeutic effect due to its wider binding range(VEGF\|A, VEGF\|B, placental growth factor), better affinity, as well as longer halflife. At present, quite a few clinical trials about Aflibercept application have completed or are undergoing. As further confirmation of its efficacy and safety goes on, Aflibercept, alone or in combination with other anti\|VEGF agents, could become a new therapeutic option for wet AMD.  (Int Rev Ophthalmol, 2014, 38:   294-300)